{"id":539758,"date":"2021-04-21T19:14:01","date_gmt":"2021-04-21T19:14:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=539758"},"modified":"2021-04-21T19:14:01","modified_gmt":"2021-04-21T19:14:01","slug":"er-her2-ve-breast-cancer-pipeline-assessment-key-companies-and-emerging-drugs","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/er-her2-ve-breast-cancer-pipeline-assessment-key-companies-and-emerging-drugs_539758.html","title":{"rendered":"ER+\/ HER2 -ve Breast Cancer Pipeline Assessment, Key Companies, And Emerging Drugs"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1588078163.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"ER+\/ HER2 -ve Breast Cancer Pipeline Assessment, Key Companies, And Emerging Drugs\" src=\"https:\/\/www.abnewswire.com\/uploads\/1588078163.png\" alt=\"ER+\/ HER2 -ve Breast Cancer Pipeline Assessment, Key Companies, And Emerging Drugs\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/p>\n<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">&#8220;ER+\/ HER2 -ve Breast Cancer Pipeline Insight, 2021&#8221; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the ER+\/ HER2 -ve Breast Cancer Market.<\/div>\n<p style=\"text-align: justify;\">The <strong>ER+\/ HER2 -ve Breast Cancer Pipeline report<\/strong> embraces in-depth commercial and clinical assessment of the ER+\/ HER2 -ve Breast Cancer pipeline products from the pre-clinical developmental phase to the marketed phase.&nbsp;<\/p>\n<p style=\"text-align: justify;\">The report covers a detailed description of the drug including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, <strong>ER+\/ HER2 -ve Breast Cancer collaborations<\/strong>, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\"><strong>Get FREE sample copy at:&nbsp;<\/strong><br \/><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/er-her2-ve-breast-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/er-her2-ve-breast-cancer-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">The available <strong>therapeutics treatment options in ER-positive\/HER2-negative Breast Cancer<\/strong>&nbsp;landscape aim to reduce the survival rate of the patient population. Conventionally, endocrine therapies are recommended as first-line treatment management options for ER-Positive breast cancer. And, if ET does not respond well then chemotherapy is suggested by the oncologist.<\/p>\n<p style=\"text-align: justify;\"><strong>ER+\/ HER2 -ve Breast Cancer Companies:<\/strong><br \/>Jiangsu HengRui Medicine<br \/>Odonate Therapeutics<br \/>Merck Sharp and Dohme<br \/>GlaxoSmithKline<br \/>Pfizer<br \/>Novartis<br \/>AstraZeneca Pharmaceuticals<br \/>Eli Lilly<br \/>Pharmacia and Upjohn Company<br \/>Radius Pharmaceuticals<br \/>Immunomedics<br \/>Roche<br \/>Syndax Pharmaceuticals<br \/>Merrimack Pharmaceuticals<br \/>Takeda Pharmaceuticals<br \/>Eagle Pharmaceuticals<br \/>Bayer<br \/><strong>And many others.<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><strong>ER+\/ HER2 -ve Breast Cancer Therapies covered in the report include:<\/strong><br \/><\/strong>Pembrolizumab<br \/>Sapanisertib<br \/>GSK525762<br \/>Radium-223 dichloride<br \/>Entinostat<br \/>Venclexta<br \/>Ipatasertib<br \/>Sacituzumab govitecan<br \/>Elacestrant (RAD1901)<br \/>Tesetaxel<br \/>SHR6390<strong><br \/><strong>And many others.<\/strong><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"ER+\/ HER2 -ve Breast Cancer Pipeline Analysis\" src=\"https:\/\/www.abnewswire.com\/uploads\/adb02120e0e578f4293165697ac3c167.jpg\" alt=\"ER+\/ HER2 -ve Breast Cancer Pipeline Analysis\" \/><\/strong><\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/er-her2-ve-breast-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>ER+\/ HER2 -ve Breast Cancer Pipeline Analysis<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report provides insights into:&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides detailed insights about companies that are developing therapies for the <strong>treatment of ER+\/ HER2 -ve Breast Cancer<\/strong> with aggregate therapies developed by each company for the same.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late stage of development for the ER+\/ HER2 -ve Breast Cancer Treatment.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>ER+\/ HER2 -ve Breast Cancer key companies<\/strong> involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">ER+\/ HER2 -ve Breast Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the <strong>ER+\/ HER2 -ve Breast Cancer market<\/strong>.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">The report is built using data and information traced from the researcher&#8217;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Scope of the report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The<strong> ER+\/ HER2 -ve Breast Cancer Pipeline Report<\/strong> provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for ER+\/ HER2 -ve Breast Cancer across the complete product development cycle, including all clinical and non-clinical stages.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It comprises detailed profiles of <strong>ER+\/ HER2 -ve Breast Cancer therapeutic products<\/strong> with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Detailed research and development progress and <strong>clinical trial of ER+\/ HER2 -ve Breast Cancer<\/strong>, results wherever available, are also included in the pipeline study.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Coverage of dormant and discontinued pipeline projects along with the reasons if available across ER+\/ HER2 -ve Breast Cancer.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Report Highlights<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">A better understanding of disease pathogenesis contributing to the development of <strong>novel therapeutics for ER+\/ HER2 -ve Breast Cancer<\/strong>.&nbsp;&nbsp;&nbsp;&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">In the coming years, the <strong>ER+\/ HER2 -ve Breast Cancer market<\/strong> is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The companies and academics are working to assess challenges and seek opportunities that could influence <strong>ER+\/ HER2 -ve Breast Cancer Research &amp; Development<\/strong>. The therapies under development are focused on novel approaches to treat\/improve the disease condition.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">A detailed portfolio of major pharma players who are involved in fueling the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/er-her2-ve-breast-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>ER+\/ HER2 -ve Breast Cancer treatment market<\/strong><\/a>. Several potential therapies for ER+\/ HER2 -ve Breast Cancer are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the ER+\/ HER2 -ve Breast Cancer market size in the coming years.&nbsp;&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Our in-depth analysis of the <strong>ER+\/ HER2 -ve Breast Cancer pipeline assets<\/strong> (in early-stage, mid-stage, and late stage of development) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. ER+\/ HER2 -ve Breast Cancer&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. ER+\/ HER2 -ve Breast Cancer Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. ER+\/ HER2 -ve Breast Cancer &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. ER+\/ HER2 -ve Breast Cancer Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. ER+\/ HER2 -ve Breast Cancer Mid Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. ER+\/ HER2 -ve Breast Cancer Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. ER+\/ HER2 -ve Breast Cancer Product Profiles<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. ER+\/ HER2 -ve Breast Cancer Key Companies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. ER+\/ HER2 -ve Breast Cancer Key Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. ER+\/ HER2 -ve Breast Cancer Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. ER+\/ HER2 -ve Breast Cancer Future Perspectives<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. ER+\/ HER2 -ve Breast Cancer Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em><strong>*The table of contents is not exhaustive; the final content may vary.&nbsp;<\/strong><\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Latest Reports By DelveInsight<br \/><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/er-her2-ve-breast-cancer-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\">ER+\/ HER2 -ve Breast Cancer Market<br \/><\/a><\/strong>DelveInsight&#8217;s ER+\/ HER2 -ve Breast Cancer Market Insights, Epidemiology and Market Forecast 2030 report provides a detailed overview of the disease and an in-depth understanding of ER+\/ HER2 -ve Breast Cancer market trends for the 7MM.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Latest Healthcare Blog &#8211;<\/strong>&nbsp;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/blog\/alpha-1-antitrypsin-deficiency-treatment-market-and-key-companies\/?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\">Alpha-1 Antitrypsin Deficiency Treatment Market<\/p>\n<p><\/a><\/strong><strong>About DelveInsight<br \/><\/strong>DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com\/_57048.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=er-her2-ve-breast-cancer-pipeline-assessment-key-companies-and-emerging-drugs\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"http:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"http:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=er-her2-ve-breast-cancer-pipeline-assessment-key-companies-and-emerging-drugs\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP &#8220;ER+\/ HER2 -ve Breast Cancer Pipeline Insight, 2021&#8221; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the ER+\/ HER2 -ve Breast Cancer Market. The ER+\/ HER2 -ve Breast Cancer &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/er-her2-ve-breast-cancer-pipeline-assessment-key-companies-and-emerging-drugs_539758.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,403,404],"tags":[],"class_list":["post-539758","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/539758","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=539758"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/539758\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=539758"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=539758"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=539758"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}